NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report issued on Sunday. The brokerage set a “hold” rating on the stock.

NovaBay Pharmaceuticals Trading Up 48.9 %

NBY opened at $0.74 on Friday. The company has a fifty day simple moving average of $0.79 and a 200 day simple moving average of $2.49. The firm has a market cap of $800,680.00, a price-to-earnings ratio of -0.01 and a beta of 0.73. NovaBay Pharmaceuticals has a twelve month low of $0.36 and a twelve month high of $17.74.

NovaBay Pharmaceuticals (NYSE:NBY) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($1.37) EPS for the quarter. NovaBay Pharmaceuticals had a negative net margin of 91.86% and a negative return on equity of 744.33%. The company had revenue of $2.40 million for the quarter. On average, analysts forecast that NovaBay Pharmaceuticals will post -0.17 earnings per share for the current fiscal year.

Institutional Trading of NovaBay Pharmaceuticals

A hedge fund recently bought a new stake in NovaBay Pharmaceuticals stock. Armistice Capital LLC purchased a new stake in shares of NovaBay Pharmaceuticals, Inc. (NYSE:NBY) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 718,768 shares of the company’s stock, valued at approximately $147,000. Armistice Capital LLC owned 11.01% of NovaBay Pharmaceuticals at the end of the most recent reporting period. 23.25% of the stock is currently owned by institutional investors and hedge funds.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.